Clinical Trial Update: A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment [Phase 1]

View source ↗

Summary

Phase 1 trial update on LOXO-260 for RET-altered cancers that progressed after prior treatment, including Non-Small Cell Lung Cancer and Thyroid Neoplasms. The …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Thyroid Neoplasms

Drugs mentioned

• LOXO-260

Snippet

Sponsor: Eli Lilly and Company | Conditions: Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms | Phase 1 | Status: ACTIVE_NOT_RECRUITING